Quantitative and qualitative differences in use and trends of hematopoietic stem cell transplantation: A Global Observational Study

Haematologica

Volumn 98, Issue 8, 2013, Pages 1282-1290

  Gratwohl, Alois ^a   Baldomero, Helen ^a   Gratwohl, Michael ^b   Aljurf, Mahmoud ^c   Bouzas, Luis Fernando ^d   Horowitz, Mary ^e   Kodera, Yoshihisa ^f   Lipton, Jeff ^g   Iida, Minako ^f   Pasquini, Marcelo C ^e   Passweg, Jakob ^a   Szer, Jeff ^h   Madrigal, Alejandro ⁱ   Frauendorfer, Karl ^b   Niederwieser, Dietger ^j  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY OF ST GALLEN   (Switzerland)

^c KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

^d INSTITUTO NACIONAL DE CÂNCER   (Brazil)

^e MEDICAL COLLEGE OF WISCONSIN   (United States)

^f AICHI MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g PRINCESS MARGARET HOSPITAL   (Canada)

^h ROYAL MELBOURNE HOSPITAL   (Australia)

ⁱ ANTHONY NOLAN RESEARCH INSTITUTE   (United Kingdom)

^j UNIVERSITY HOSPITAL LEIPZIG   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOIMMUNE DISEASE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; COST EFFECTIVENESS ANALYSIS; DONOR; ECONOMIC EVALUATION; HEALTH CARE COST; HEALTH SURVEY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INCOME; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MYELODYSPLASTIC SYNDROME; OBSERVATIONAL STUDY; RETROSPECTIVE STUDY; SOLID TUMOR; WORLD HEALTH ORGANIZATION;

GROSS DOMESTIC PRODUCT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; REGISTRIES; RETROSPECTIVE STUDIES; WORLD HEALTH; WORLD HEALTH ORGANIZATION;

EID: 84880968130     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2012.076349     Document Type: Article

References (37)

1. Horowitz M.M. Uses and growth of hematopoietic cell transplantation. In "Thomas' hematopoietic cell transplantation" (Appelbaum FR, Forman SJ, Negrin RS, Blume KG, eds) p 15-21; 2009 Wiley-Blackwell, Oxford.
2. Gratwohl A, Passweg J, Baldomero H, Horisberger B, Urbano-Ispizua A; Accreditation Committee of the European Group for Blood and Marrow Transplantation (EBMT). Economics, health care systems and utilization of haematopoietic stem cell transplants in Europe. Br J Haematol. 2002;117(2):451-68.
3. Copelan EA. Hematopoietic stem-cell transplantation. N Engl J Med. 2006;354(17): 1813-26.
4. Appelbaum FR. Hematopoietic-cell transplantation at 50. N Engl J Med. 2007;357(15): 1472-5.
5. Gooley TA, Chien JW, Pergam SA, Hingorani S, Sorror ML, Boeckh M, et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med. 2010;363 (22):2091-101.
6. Halter J, Schüpbach WM, Casali C Elhasid R, Fay K, Hammans S, et al. Allogeneic hematopoietic SCT as treatment option for patients with mitochondrial neurogastrointestinal encephalomyopathy (MNGIE): a consensus conference proposal for a standardized approach. Bone Marrow Transplant. 2011;46(3):330-7.
7. Wagner JE, Ishida-Yamamoto A, McGrath JA, Hordinsky M, Keene DR, Woodley DT, et al. Bone marrow transplantation for recessive dystrophic epidermolysis bullosa. N Engl J Med. 2010;363(14):629-39.
8. Sorror ML, Sandmaier BM, Storer BE, Franke GN, Laport GG, Chauncey TR, et al. Longterm outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies. JAMA. 2011;306(17):1874-83.
9. Pasquini MC, Wang Z, Horowitz MM, Hordinsky M, Keene DR, Woodley DT, et al. 2010 report from the Center for International Blood and Marrow Transplant Research (CIBMTR): current uses and outcomes of hematopoietic cell transplants for blood and bone marrow disorders. Clin Transpl. 2010:87-105.
10. World Health Organization. WHO guiding principles on human cell, tissue and organ transplantation. Transplantation. 2010;90(3): 229-33.
11. Sixty-Third World Health Assembly, World Health Organization. WHO guiding principles on human cell, tissue and organ transplantation. Cell Tissue Bank. 2010;11(4): 413-9.
12. Gratwohl A, Baldomero H, Aljurf M, Pasquini MC, Bouzas LF, Yoshimi A, et al. Hematopoietic stem cell transplantation: a global perspective. JAMA 2010;303(16): 1617-24.
13. Baldomero H, Gratwohl M, Gratwohl A, Tichelli A, Niederwieser D, Madrigal A, et al; European Group for Blood and Marrow Transplantation EBMT. The EBMT activity survey 2009: trends over the past 5 years. Bone Marrow Transplant. 2011;46(4):485-501.
14. Yoshimi A, Suzuki R, Atsuta Y, Iida M, Lu DP, Tong W, et al. Hematopoietic SCT activity in Asia: a report from the Asia-Pacific Blood and Marrow Transplantation Group. Bone Marrow Transplant. 2010;45(12):1682-91.
15. Mohamed SY, Fadhil I, Hamladji RM, Hamidieh AA, Fahmy O, Ladeb S, et al. Hematopoietic stem cell transplantation in the Eastern Mediterranean Region (EMRO) 2008-2009: report on behalf of the Eastern Mediterranean Bone Marrow Transplantation (EMBMT) Group. Hematol Oncol Stem Cell Ther. 2011;4(2):81-93.
16. Moore AS, Shaw PJ, Hallahan AR, Carter TL, Kilo T, Nivison-Smith I, et al. Haemopoietic stem cell transplantation for children in Australia and New Zealand, 1998-2006: a report on behalf of the Australasian Bone Marrow Transplant Recipient Registry and the Australian and New Zealand Children's Haematology Oncology Group. Med J Aust. 2009;190 (3):121-5.
17. Leelahavarong P, Chaikledkaew U, Hongeng S, Kasemsup V, Lubell Y, Teerawattananon Y. A cost-utility and budget impact analysis of allogeneic hematopoietic stem cell transplantation for severe thalassemic patients in Thailand. BMC Health Serv Res. 2010;10: 209.
18. Gratwohl A, Baldomero H, Schwendener A, Gratwohl M, Urbano-Ispizua A, Frauendorfer K. Hematopoietic stem cell transplants for chronic myeloid leukemia in Europe--impact of cost considerations. Leukemia. 2007;21(3):383-6.
19. Saussele S, Lauseker M, Gratwohl A, Beelen DW, Bunjes D, Schwerdtfeger R, et al. Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV. Blood. 2010;115 (10):1880-5.
20. Gajewski JL, Robinson P. Do affluent societies have the only options for the best therapy? Leukaemia. 2007;21(3):387-8.
21. Ruiz-Argüelles GJ. Whither the bone marrow transplant? Hematology. 2010;15(1):1-3.
22. Tan SS, Uyl-de Groot CA, Huijgens PC, Fibbe WE. Stem cell transplantation in Europe: trends and prospects. Eur J Cancer. 2007;43(16):2359-65.
23. Ashfaq K, Yahaya I, Hyde C, Andronis L, Barton P, Bayliss S, et al. Clinical effectiveness and cost-effectiveness of stem cell transplantation in the management of acute leukaemia: a systematic review. Health Technol Assess. 2010;14(54):1-141.
24. Costa V, McGregor M, Laneuville P, Brophy JM. The cost-effectiveness of stem cell transplantations from unrelated donors in adult patients with acute leukemia. Value Health. 2007;10(4):247-55.
25. Gratwohl A, Schwendener A, Baldomero H, Gratwohl M, Apperley J, Niederwieser D, et al. Changes in the use of hematopoietic stem cell transplantation: a model for diffusion of medical technology. Haematologica. 2010;95 (4):637-43.
26. Berry DA, Ueno NT, Johnson MM, Lei X, Caputo J, Rodenhuis S, et al. High-dose chemotherapy with autologous stem-cell support as adjuvant therapy in breast cancer: overview of 15 randomized trials. J Clin Oncol. 2011;29(24):3214-23.
27. Sinha SR, Barry M. Health technologies and innovation in the global health arena. New Engl J Med. 2011;365(9):779-82.
28. Majhail NS, Omondi NA, Denzen E, Murphy EA, Rizzo JD. Access to hematopoietic cell transplantation in the United States. Biol Blood Marrow Transplant. 2010;16(8):1070-5.
29. Shaw BE, Arguello R, Garcia-Sepulveda CA, Madrigal JA. The impact of HLA genotyping on survival following unrelated donor haematopoietic stem cell transplantation. Br J Haematol. 2010;150(3):251-8.
30. Confer D, Robinett P. The US National Marrow Donor Program role in unrelated donor hematopoietic cell transplantation. Bone Marrow Transplant. 2008;42 (Suppl 1):S3-S5.
31. Wang W.C. Sickle cell anemia and other sickling syndromes. In: Wintrobe's Clinical Hematology (Greer JP, Foerster J, Rodgers GM, Paraskevas F, Glader B, Arber DA, Means RT, eds). p 1038-1082. Wolters Kluwer, Lippincott Williams & Wilkins, Philadelphia, Baltimore, New York, London 2009.
32. Borgna-Pignatti C, Galanello R. Thalassemias and related disorders. In: Wintrobe's Clinical Hematology (Greer JP, Foerster J, Rodgers GM, Paraskevas F, Glader B, Arber DA, Means RT, eds). p 1083-1131. Wolters Kluwer, Lippincott Williams & Wilkins, Philadelphia, Baltimore, New York, London 2009.
33. Gratwohl A, Brand R, Niederwieser D, Baldomero H, Chabannon C, Cornelissen J, et al. Introduction of a quality management system and outcome after hematopoietic stem-cell transplantation. J Clin Oncol. 2011;29(15):1980-6.
34. Gyurkocza B, Rezvani A, Storb RF. Allogeneic hematopoietic cell transplantation: the state of the art. Expert Rev Hematol. 2010;3(3):285-99.
35. Gratwohl A. The EBMT risk score. Bone Marrow Transplant. 2012;47(6):749-56
36. Giebel S, Labopin M, Ehninger G, Beelen D, Blaise D, Ganser A, et al. Association of Human Development Index with rates and outcomes of hematopoietic stem cell transplantation for patients with acute leukemia. Blood. 2010;116(1):122-8.
37. Brawley O, Byers T, Chen A, Pignone M, Ransohoff D, Schenk M, et al. New American Cancer Society process for creating trustworthy cancer screening guidelines. JAMA 2011; 306(22):2495-9.